Methotrexate-induced senescence in human adenocarcinoma cells is accompanied by induction of p21waf1/cip1 expression and lack of polyploidy

Cancer Letters

Volumn 284, Issue 1, 2009, Pages 95-101

  Dabrowska, Magdalena ^a   Mosieniak, Grazyna ^a   Skierski, Janusz ^b   Sikora, Ewa ^a   Rode, Wojciech ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

Accelerated senescence; Colorectal adenocarcinoma; Growth arrest; High dose methotrexate; Multinucleation

Indexed keywords

BETA GALACTOSIDASE; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; METHOTREXATE;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL NUCLEUS; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DNA CONTENT; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN CELL; KARYOTYPE; POLYPLOIDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENESCENCE;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; METHOTREXATE; POLYPLOIDY;

EID: 69049117190     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.04.015     Document Type: Article

References (40)

1. Schornagel J.H., and McVie J.G. The clinical pharmacology of methotrexate. Cancer Treat. Rev. 10 (1983) 53-75
2. Li J.C., and Kaminskas E. Accumulation of DNA strand breaks and methotrexate cytotoxicity. Proc. Natl. Acad. Sci. USA 81 (1984) 5694-5698
3. 10-propargyl-5,8-dideazafolic acid. Cancer Res. 48 (1988) 2036-2041
4. Houghton J.A. Antimetabolites. In: Gewirtz D.A., Holt S.E., and Grant S. (Eds). Cancer Drug Discovery and Development. Apoptosis, Senescence and Cancer (2007), Humana Press Inc., Totowa, NJ 361-382
5. Hatse S., De Clercq E., and Balzarini E. Role of antimetabolites of purine and pyrimidine nucleotide metabolism in tumor cell differentiation. Biochem. Pharmacol. 58 (1999) 539-555
6. Singh R., Fouladi-Nashta A.A., Halliday N., Barrett D.A., and Sinclair K.D. Methotrexate induced differentiation in colon cancer cells is primarily due to purine deprivation. J. Cell. Biochem. 99 (2006) 146-155
7. Hattangadi D.K., DeMasters G.A., Walker T.D., Jones K.R., Di X., Newsham I.F., and Gewirtz D.A. Influence of p53 and caspase 3 on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem. Pharmacol. 68 (2004) 1699-1708
8. Assaraf Y.G. Molecular basis of antifolate resistance. Cancer Metast. Rev. 26 (2007) 153-181
9. Campisi J., and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat. Rev. Mol. Cell Biol. 8 (2007) 729-740
10. Bartek J., Hodny Z., and Lukas J. Cytokine loops driving senescence. Nat. Cell Biol. 10 (2008) 887-889
11. Collado M., and Serrano M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 6 (2006) 472-476
12. d'Adda di Fagagna F. Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8 (2008) 512-522
13. Schmitt C.A. Cellular senescence and cancer treatment. Biochem. Biophys. Acta 1775 (2007) 5-20
14. Gewirtz D.A., Holt S.E., and Elmore L.W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem. Pharmacol. 76 (2008) 947-957
15. Roninson I. Tumor cell senescence in cancer treatment. Cancer Res. 63 (2003) 2705-2715
16. Dabrowska M., Hendrikx J.P., Skierski J., Malinowska M., Bertino J.R., and Rode W. EGFP fluorescence as an indicator of cancer cells response to methotrexate. Eur. J. Pharmacol. 555 (2007) 93-99
17. Longo G.S.A., Izzo J., Gorlick R., Banerjee D., Jhanwar S.C., and Bertino J.R. Characterization and drug sensitivity of four newly established colon adenocarcinoma cell lines to antifolate inhibitors of thymidylate synthase. Oncol. Res. 12 (2000) 309-314
18. Sliwinska M.A., Mosieniak G., Wolanin K., Babik A., Piwocka K., Magalska A., Szczepanowska J., Fronk J., and Sikora E. Induction of senescence with doxorubicin leads to increased genomic instability of HCT116 cells. Mech. Ageing Dev. 130 (2009) 24-32
19. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Meth. 139 (1991) 271-279
20. Jolivet J., Cowan K.H., Curt G.A., Clendeninn N.J., and Chabner B.A. The pharmacology and clinical use of methotrexate. New Engl. J. Med. 309 (1983) 1094-1104
21. Zelcer S., Kellick M., Wexler L.H., Gorlick R., and Meyers P.A. The memorial sloan kettering cancer center experience with outpatient administration of high dose methotrexate with leucovorin rescue, Pediatr. Blood Cancer 50 (2008) 1176-1180
22. Blagosklonny M.V. Cell senescence and hypermitogenic arrest. EMBO Rep. 4 (2003) 358-362
23. Rajaraman R., Rajaraman M.M., Rajaraman S.R., and Guernsey D.L. Neosis - a paradigm of self renewal in cancer. Cell Biol. Int. 29 (2005) 1084-1097
24. Taylor I.W., and Tattersall M.H.N. Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry. Cancer Res. 41 (1981) 1549-1558
25. Tsurusawa M., Niwa M., Katano N., and Fujimoto T. Flow cytometric analysis by bromodeoxyuridine/DNA assai of cell cycle perturbation of methotrexate-treated mouse L1210 leukemia cells. Cancer Res. 48 (1988) 4288-4293
26. Ganem N.J., Storchova Z., and Pellman D. Tetraploidy, aneuploidy and cancer. Curr. Opinion Gen. Dev. 17 (2007) 157-162
27. Storchova Z., and Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat. Rev. Mol. Cell Biol. 5 (2004) 45-54
28. Kroemer G., Galluzzi L., Vandenabeele P., Abrams J., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., El-Deiry W.S., Golstein P., Green D.R., Hengartner M., Knight R.A., Kumar S., Lipton S.A., Malorni W., Nunez G., Peter M.E., Tschopp J., Yuan J., Piacentini M., Zhivotovsky B., and Mellino G. Classification of cell death: recommendations of the nomenclature committee on cell death 2009. Cell Death Differ. 16 (2009) 3-11
29. Shay J.W., and Roninson I.B. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23 (2004) 2919-2933
30. Lengauer C., Kinzler K.W., and Vogelstein B. Genetic instability in colorectal cancers. Nature 386 (1997) 623-627
31. Morales C., Ribas M., Aiza G., and Peinado M.A. Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells. Oncogene 24 (2005) 6842-6847
32. Illidge T.M., Cragg M.S., Fringes B., Olive P., and Erenpreisa J.A. Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. Cell Biol. Int. 24 (2000) 621-633
33. Meek D.W. The role of p53 in the response to mitotic spindle damage. Pathol. Biol. 48 (2000) 246-254
34. Vogel C., Kienitz A., Hofmann I., Muller R., and Bastians H. Crosstalk of the mitotic spindle assembly checkpoint with p53 to prevent polyploidy. Oncogene 23 (2004) 6845-6853
35. Puig P.-E., Guilly M.-N., Bouchot A., Droin N., Cathelin D., Bouyer F., Favier L., Ghiringhelli F., Kroemer G., Solary E., Martin F., and Chauffert B. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol. Int. 32 (2008) 1031-1043
36. Sundaram M., Guernsey D.L., Rajaraman M.M., and Rajaraman R. Neosis - a novel type of cell division in cancer. Cancer Biol. Ther. 3 (2004) 207-218
37. Erenpreisa J.A., Cragg M.S., Fringes B., Sharakhov I., and Illidge T.M. Release of mitotic descendants by giant cells from irradiated Burkitt's lymphoma cell lines. Cell Biol. Int. 24 (2000) 635-648
38. Roberson R.S., Kussick S.J., Vallieres E., Chen S.-Y.J., and Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res. 65 (2005) 2795-2803
39. Jones K.R., Elmore L.W., Jackson-Cook C., Demasters G., Povirk L.F., Holt S.E., and Gewirtz D.A. p53-dependent accelerated senescence induced by ionizing radiation in breast tumor cells. Int. J. Radiat. Biol. 81 (2005) 445-458
40. Chang B.-D., Broude E.V., Dokmanovic M., Zhu H., Ruth A., Xuan Y., Kandel E.S., Lausch E., Christov K., and Roninson I.B. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 59 (1999) 3761-3767